NCT07091825

Evaluating the Efficacy and Safety of Contact Lens Lubricant in Rigid Gas Permeable Corneal Contact Lens Wearers

Recruiting now NA Last updated 29 July 2025

What this trial tests

NA trial testing LACRIFRESH OCU-DRY 0.3% OSD in Myopia in 152 participants. Currently enrolling.

Timeline

27 June 2025

Primary endpoint
30 March 2026

30 June 2026

Quick facts

Lead sponsor	Avizor SA
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	152
Start date	27 June 2025
Primary completion	30 March 2026
Estimated completion	30 June 2026
Sites	3 locations across China

Drugs / interventions tested

• LACRIFRESH OCU-DRY 0.3% OSD
• Rigid contact lens lubricant

Conditions studied

• Myopia — all drugs for Myopia →

Sponsor

Avizor SA

Who can join

8 and older, any sex, with Myopia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial aims to evaluate the safety and effectiveness of LACRIFRESH OCU-DRY 0.3% OSD, a contact lens lubricant produced by AVIZOR, S.A. This clinical trial adopts a Multi-center, randomized, open-label, positive parallel-controlled design in accordance with the principles outlined in the Norms on the Quality Management for the Clinical Trials of Medical Devices issued by the National Medical Products Administration of China.

Meanwhile, following statistical requirements, 152 rigid contact lens wearers are planned to be enrolled after screening and meeting the inclusion criteria. Participants will be randomly assigned to groups and provided with lenses, lubricants, and care solutions accordingly. Clinical follow-up assessments are scheduled at 1 week, 1 month, and 3 months after use.

The primary efficacy indexes are the percentage of patients with binocular comfort score ≥ Level 3 at the 1-month follow-up and the percentage of patients with best corrected distance visual acuity with contact lenses for both eyes ≥5.0 at the 1-month follow-up after using the contact lens lubricant. Secondary efficacy indexes include, best corrected distance visual acuity with lenses, visual acuity with lenses, residual diopter, tear break-up time, uncorrected visual acuity, examination of contact lens fitting status, lens assessment, and contact lens lubricant evaluation during the corresponding follow-up periods. Safety indexes include slit lamp examination, fundus examination, IOP, corneal endothelial cell, adverse events, serious adverse events, device defects that may lead to serious adverse events, other device defects during the corresponding follow-up periods.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.